scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding FUROSCIX Indication in Heart Failure Page 1

FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class

Expansion of the indication allows the use of FUROSCIX in patients with chronic heart failure in NYHA class IV